Neurodegenerative brain disease and trauma affect over 35 million patients worldwide, accounting for over $1.3 trillion of nondiscretionary healthcare spending every year.  

Unfortunately, failed drug trials, ineffective treatments, and delayed diagnoses limit therapeutic options. The lack of blood testing products as tools for breakthrough discoveries in drug R&D, limiting pipeline advancement is a significant gap that ZelosDx addresses with our patented technology.